2023-507409-32-00CompletedPhase 1
A study to investigate the safety, pharmacodynamics and pharmacokinetics of increasing doses of subcutaneously administered deuterated DMT (CYB004) in healthy subjects
Source: EU CTIS (euclinicaltrials.eu) · Last updated 14 Dec 2023
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 72 (actual)
- First submitted
- 23 Oct 2023
- Start date
- 4 Dec 2023
- Lead sponsor
- Cybin IRL Limited
- EU CT number
- 2023-507409-32-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 72
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre for Human Drug Research | Leiden | Netherlands | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.